For research use only, not for therapeutic use.
MIR96-IN-1(Cat No.:I001196)is a selective inhibitor targeting the methyltransferase SETD8, which is responsible for monomethylating histone H4 at lysine 20 (H4K20me1). By inhibiting SETD8, MIR96-IN-1 disrupts the epigenetic regulation of gene expression, potentially leading to the reactivation of silenced tumor suppressor genes. This compound has shown promise in preclinical studies, particularly in cancer models where aberrant SETD8 activity contributes to tumorigenesis. MIR96-IN-1’s ability to modulate histone methylation provides valuable insights into developing targeted therapeutic strategies aimed at addressing epigenetic alterations in various cancers.
Catalog Number | I001196 |
CAS Number | 1311982-88-3 |
Molecular Formula | C33H48N8O2 |
Purity | ≥95% |
Target | microRNA-96 |
Solubility | 10 mM in DMSO |
Storage | Store at -20°C |
IUPAC Name | N-(3-azidopropyl)-4-[2,6-ditert-butyl-4-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]phenoxy]butanamide |
InChI | InChI=1S/C33H48N8O2/c1-32(2,3)25-20-23(31-37-27-12-11-24(22-28(27)38-31)41-17-15-40(7)16-18-41)21-26(33(4,5)6)30(25)43-19-8-10-29(42)35-13-9-14-36-39-34/h11-12,20-22H,8-10,13-19H2,1-7H3,(H,35,42)(H,37,38) |
InChIKey | LTPQCIXFOJELHJ-UHFFFAOYSA-N |
SMILES | CC(C)(C)C1=CC(=CC(=C1OCCCC(=O)NCCCN=[N+]=[N-])C(C)(C)C)C2=NC3=C(N2)C=C(C=C3)N4CCN(CC4)C |
Reference | <p style=/line-height:25px/> |